Targeting TMPRSS2 ERG in Prostate Cancer
Technical Report,01 Sep 2015,31 Aug 2016
Dana-Farber Cancer Institute Boston United States
Pagination or Media Count:
TMPRSS2-ERG is an oncogenic translocation present in approximately half of all prostate cancers. Despite being an attractive therapeutic target, transcription factors have historically been difficult target pharmacologically. Furthermore, the exact of ERG in mediating tumorigenesis is unknown making it difficult to develop physiologically relevant assays to measure its activity.